Merit Medical Introduces Viceroy Inflation Device.

SOUTH JORDAN, Utah -- Merit Medical Systems, Inc. (Nasdaq/NMS:MMSI), a leading manufacturer and marketer of proprietary disposable accessories used primarily in cardiology and radiology procedures, announced full market release of its new Viceroy(TM) inflation device today.

The Viceroy is the fifth inflation device, and the third analog inflation device, to be added to Merit's inflation device line that already has approximately 50% worldwide market share. The Viceroy offers patented technology, and its design allows for faster inflations and deflations. A 60 ml size, which is a new size for Merit, will allow sales to previously untapped markets. The 10 and 20 ml sizes will add to Merit's leadership position. The second of seven new Merit products scheduled for release by the end of the year, the Viceroy represents an estimated market opportunity of $15-20 million.

"The Viceroy targets expanded international markets and previously inaccessible opportunities in radiology, urology, gastrointestinal and OEM markets," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "The new 60 ml size also creates the opportunity for Merit to become involved in valvuloplasty and peripheral interventional procedures."

ABOUT MERIT

Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical accessories used in interventional and diagnostic procedures, particularly in cardiology and radiology. Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 70 individuals. Merit employs approximately 1,440 people worldwide, with manufacturing facilities in Salt Lake City and South Jordan, Utah; Santa Clara, California; Angleton, Texas; Richmond, Virginia; Maastricht, The Netherlands; and Galway, Ireland.

Statements contained in this release which are not purely historical are forward-looking statements within the meaning of the Private Securities Litigation Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2004. Such risks and uncertainties include market acceptance of new products, introduction of products in a timely fashion, product recalls, delays in obtaining regulatory approvals, or the failure to maintain such approvals, cost increases, fluctuations in and obsolescence of inventory, price and product competition, availability of labor and materials, development of new products and technology that could render our products obsolete, product liability claims, modification or limitation of governmental or private insurance reimbursement, infringement of our technology or the assertion that our technology infringes the rights of other parties, foreign currency fluctuations, challenges associated with the Company's growth strategy, changes in health care markets related to health care reform initiatives, litigation and other factors referred to in the Company's 10-K and other reports filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results may differ materially from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.